Abstract
The pyrazolopyridine stimulators of soluble guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue. These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.
MeSH terms
-
Administration, Oral
-
Animals
-
Aorta / drug effects
-
Blood Pressure / drug effects
-
Crystallography, X-Ray
-
Dogs
-
Enzyme Activation / drug effects
-
Guanylate Cyclase / chemistry
-
Guanylate Cyclase / metabolism*
-
In Vitro Techniques
-
Injections, Intravenous
-
Lung / drug effects
-
Lung / enzymology
-
Molecular Structure
-
Morpholines / administration & dosage
-
Morpholines / blood
-
Morpholines / metabolism*
-
Morpholines / pharmacology*
-
Nitric Oxide / metabolism
-
Pyrazoles / administration & dosage
-
Pyrazoles / blood
-
Pyrazoles / metabolism*
-
Pyrazoles / pharmacology*
-
Pyridines / administration & dosage
-
Pyridines / blood
-
Pyridines / metabolism*
-
Pyridines / pharmacology*
-
Pyrimidines / administration & dosage
-
Pyrimidines / blood
-
Pyrimidines / metabolism*
-
Pyrimidines / pharmacology*
-
Rats
-
Rats, Wistar
-
Solubility
-
Vasodilation / drug effects
Substances
-
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
-
BAY 41-8543
-
Morpholines
-
Pyrazoles
-
Pyridines
-
Pyrimidines
-
pyrazolopyridine
-
Nitric Oxide
-
Guanylate Cyclase